Medulloblastoma (MB) is the most common malignant brain tumor of childhood. Although
outcomes have improved in recent decades, new treatments are still needed to improve …

Background Much effort has been devoted to the discovery of specific mechanisms between
drugs and single targets to date. However, as biological systems maintain homeostasis at …

A new type of signaling network element, called cancer signaling bridges (CSB), has been
shown to have the potential for systematic and fast-tracked drug repositioning. On the basis …

Outcomes of anticancer therapy vary dramatically among patients due to diverse genetic
and molecular backgrounds, highlighting extensive intertumoral heterogeneity. The …

Background: In the last two decades, there have been significant technological advances in
the early detection of brain tumors. However, no notable improvements have been observed …

The highly invasive nature of glioblastoma imposes poor prospects for patient survival.
Molecular evidence indicates glioblastoma cells undergo an intriguing expansion of …

Simple Summary To date, personalized and comprehensive approaches to combat
treatment resistances and failures are limited due to the highly heterogeneous, resistive, and …

We are currently living in the “genomic era.” In the last decade, high-throughput genomic
analyses have generated massive quantities of data that can be used to explore gene …

Glioblastoma (GBM), an incurable tumor, remains difficult to model and more importantly to
treat due to its genetic/epigenetic heterogeneity and plasticity across cellular states. The …

During the last few decades, the discovery of novel targets for therapeutic intervention led to
the development of chemotherapeutic agents that specifically interfere with altered cellular …